Health & Medical / Saturday, June/01/2024 / 12

Antineoplastons (PDQ®): Complementary and alternative medicine - Health Professional Information [NC

Antineoplastons (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI]-Adverse Effects

Antineoplastons (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Adverse Effects

Antineoplastons (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] Guide

Table 3. Adverse Effects

Adverse Effect	Reference
^a The most severe adverse effects occurred in this study, which reported neurologictoxiceffects such as excessive somnolence, somnolence plusconfusion, and increased frequency of underlyingfocal motor seizures; increasedcerebraledema; and persistent confusion. In addition, the study reportedmyalgia, severecutaneous erythema,pruritus, and anasarca of the extremities and face.
Anemia	[2,3]
Blood pressureelevation	[4,5]
Dizziness or vertigo	[6,7]
Excessabdominalgas	[4,8]
Feverand chills	[2,5,6,7,9,10,11]
General malaise with and withoutanorexia	[2,4]
Headaches	[1,4,6,7]
Hypocalcemia andhypercalcemia	[2,5]
Increased thickness ofepidermisassociated with skin peeling and faster-than-usual growth of nails	[11]
Maculopapular or itchy skin rash	[2,4,5,8]
Mildmyelosuppression	[5,8,12]
Nauseaandvomiting	[1,2,5,6,7]
Neurocortical toxicity, severe	[1]^a
Numbness	[2]
Palpitations,tachycardia, or pressure in the chest with irregular heartbeat	[4,11,1,7]
Peripheraledema, facial edema, cerebral edema	[1,4]
Swelling, pain, or stiffness of small joints	[4,8,10,11]

References:

Buckner JC, Malkin MG, Reed E, et al.: Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 74 (2): 137-45, 1999.
Burzynski SR, Lewy RI, Weaver RA, et al.: Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report. Drugs R D 4 (2): 91-101, 2003.
Burzynski SR, Janicki TJ, Weaver RA, et al.: Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma. Integr Cancer Ther 5 (1): 40-7, 2006.
Tsuda H, Hara H, Eriguchi N, et al.: Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients. Kurume Med J 42 (4): 241-9, 1995.
Burzynski SR, Burzynski B, Mohabbat MO: Toxicology studies on antineoplaston AS2-1 injections in cancer patients. Drugs Exp Clin Res 12 (Suppl 1): 25-35, 1986.
Burzynski SR, Kubove E: Toxicology studies on antineoplaston A10 injections in cancer patients. Drugs Exp Clin Res 12 (Suppl 1): 47-55, 1986.
Burzynski SR, Kubove E: Phase I clinical studies of antineoplaston A3 injections. Drugs Exp Clin Res 13 (Suppl 1): 17-29, 1987.
Sugita Y, Tsuda H, Maruiwa H, et al.: The effect of Antineoplaston, a new antitumor agent on malignant brain tumors. Kurume Med J 42 (3): 133-40, 1995.
Burzynski SR, Stolzmann Z, Szopa B, et al.: Antineoplaston A in cancer therapy. (I). Physiol Chem Phys 9 (6): 485-500, 1977.
Burzynski SR: Toxicology studies on antineoplaston AS2-5 injections in cancer patients. Drugs Exp Clin Res 12 (Suppl 1): 17-24, 1986.
Burzynski SR, Kubove E, Burzynski B: Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 13 (Suppl 1): 37-43, 1987.
Burzynski SR, Weaver RA, Janicki T, et al.: Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1. Integr Cancer Ther 4 (2): 168-77, 2005.